奥氮平治疗的药物遗传学。

The pharmacogenetics of treatment with olanzapine.

机构信息

Department of Clinical Pharmacology, Hospital Universitario de La Princesa, Instituto Teófilo Hernando, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria La Princesa (IP), Madrid, 28006, Spain.

UICEC Hospital Universitario de La Princesa, Plataforma SCReN (Spanish Clinical Research Network), Instituto de Investigación Sanitaria La Princesa (IP), Madrid, 28006, Spain.

出版信息

Pharmacogenomics. 2021 Sep;22(14):939-958. doi: 10.2217/pgs-2021-0051. Epub 2021 Sep 16.

DOI:10.2217/pgs-2021-0051

PMID:34528455

Abstract

Genetic polymorphism in olanzapine-metabolizing enzymes, transporters and drug targets is associated with alterations in safety and efficacy. The aim of this systematic review is to describe all clinically relevant pharmacogenetic information on olanzapine and to propose clinically actionable variants. Two hundred and eighty-four studies were screened; 76 complied with the inclusion criteria and presented significant associations. Taq1A (rs1800497) *A1, -2548 (rs7799039) G and *1F alleles were related to olanzapine effectiveness and safety variability in several studies, with a high level of evidence. -141 (rs1799732) Ins, A-241G (rs1799978) G, Ser9Gly (rs6280) Gly, rs7997012 A, C3435T (rs1045642) T and G2677T/A (rs2032582) T and *3 alleles were related to safety, effectiveness and/or pharmacokinetic variability with moderated level of evidence.

摘要

遗传多态性在奥氮平代谢酶、转运体和药物靶点与安全性和疗效的改变有关。本系统评价的目的是描述奥氮平所有与临床相关的遗传药理学信息，并提出有临床作用的变异体。筛选了 284 项研究；76 项符合纳入标准，并呈现出显著的相关性。Taq1A(rs1800497)A1、-2548(rs7799039)G 和1F 等位基因与奥氮平在几项研究中的有效性和安全性变异性有关，具有较高的证据水平。-141(rs1799732)Ins、A-241G(rs1799978)G、Ser9Gly(rs6280)Gly、rs7997012A、C3435T(rs1045642)T 和 G2677T/A(rs2032582)T 和*3 等位基因与安全性、有效性和/或药代动力学变异性有关，具有中等水平的证据。